RAXVID Trademark
RAXVID is a USPTO trademark filed by Pfizer Inc.. Status: Pending.
Prosecution Summary
Trademark Summary
RAXVID is a standard character mark owned by Pfizer Inc. covering pharmaceutical preparations for treating a wide range of diseases and disorders including autoimmune, cardiovascular, infectious, inflammatory, cancer, diabetes, and others, plus vaccines, in International Class 005 and domestic classes 006, 018, 044, 046, 051, and 052. The application is on the Principal Register under intent-to-use basis with class 005 active. A Notice of Allowance was issued on December 2, 2025, requiring a Statement of Use or extension within six months.
Recent Activity
Filed June 9, 2025, the application advanced quickly through examination, was approved for publication September 10, 2025, and published for opposition October 7, 2025. Attorney and correspondenc
Trademark Facts
| Mark | RAXVID |
|---|---|
| Serial Number | 99225404 |
| Status | Pending |
| Filing Date | 2025-06-09 |
| Mark Type | Word |
| Nice Classes | 005 (Pharmaceuticals) |
| Owner | Pfizer Inc. |
| Attorney of Record | Yana Gorbach |
| Prosecution Events | 18 |
| Latest Event | EXRA on 2026-05-01 |
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use